Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 9, 2005, Pages 59-62

  Personeni, Nicola ^a   Hendlisz, Alain ^a   Gallez, Julien ^a   Galdon, Maria Gomez ^a   Larsimont, Denis ^a   Van Laethem, Jean Luc ^b   Nagy, Nathalie ^b   Barette, Martine ^a   Paesmans, Marianne ^a   Cardoso, Fatima ^a   Bleiberg, Harry ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN;

ADULT; AGED; AUTOPHOSPHORYLATION; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STAINING; TREATMENT RESPONSE;

EID: 30544439417     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.04.029     Document Type: Conference Paper

References (27)

1. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
2. G. Carpenter Receptors for epidermal growth factor and other polypeptide mitogens Annu Rev Biochem 56 1987 881 914
3. C. Messa, F. Russo, M.G. Caruso EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma Acta Oncol 37 1998 285 289
4. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
5. N.S. Goldstein, M. Armin Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma Implications for a standardized scoring system Cancer 92 2001 1331 1346
6. J. Mendelsohn Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clin Cancer Res 3 1997 2703 2707
7. F. Ciardiello, G. Tortora A novel approach in the treatment of cancer Targeting the epidermal growth factor receptor Clin Cancer Res 7 2001 2958 2970
8. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
9. L.B. Saltz, N.J. Meropol, P.J. Loehrer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
10. E.K. Rowinsky, G.H. Schwartz, J.A. Gollob Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer J Clin Oncol 22 2004 3003 3015
11. U. Vanhoefer, M. Tewes, F. Rojo Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol 22 2004 175 184
12. J.D. Sato, T. Kawamoto, A.D. Le Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 1983 511 529
13. T. Kawamoto, J.D. Sato, A. Le Growth stimulation of A431 cells by epidermal growth factor Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody Proc Natl Acad Sci U S A 80 1983 1337 1341
14. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res 55 1995 5536 5539
15. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
16. N. Prenzel, E. Zwick, H. Daub EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF Nature 402 1999 884 888
17. D. Graus-Porta, R.R. Beerli, J.M. Daly ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling EMBO J 16 1997 1647 1655
18. D. Liu, J. Aguirre Ghiso, Y. Estrada EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma Cancer Cell 1 2002 445 457
19. F. Ciardiello, G. Tortora Epidermal growth factor receptor (EGFR) as a target in cancer therapy Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs Eur J Cancer 39 2003 1348 1354
20. L.H. Sobin C.H. Wittekind UICC TNM Classification of Malignant Tumors (ed 5) 1997 John Wiley & Sons New York, NY
21. D.C. Allred, G.M. Clark, R. Elledge Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer J Natl Cancer Inst 85 1993 200 206
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. B. Leyland-Jones Maximizing the response to Herceptin therapy through optimal use and patient selection Anticancer Drugs 12 suppl 4 2001 S11 S17
24. C.L. Arteaga ErbB-targeted therapeutic approaches in human cancer Exp Cell Res 284 2003 122 130
25. T. Okutani, Y. Okabayashi, Y. Kido Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells J Biol Chem 269 1994 31310 31314
26. A.J. Barker, K.H. Gibson, W. Grundy Studies leading to the identification of ZD1839 (IRESSA) An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 11 2001 1911 1914
27. A.E. Wakeling, S.P. Guy, J.R. Woodburn ZD1839 (Iressa) An orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy Cancer Res 62 2002 5749 5754